Co-morbidities of diabetes mellitus among admitted stroke patients in a tertiary hospital
DOI:
https://doi.org/10.18203/2320-6012.ijrms20242920Keywords:
Co-morbidities, Diabetes mellitus, StrokeAbstract
Background: Diabetes mellitus significantly impacts stroke risk and outcomes by influencing co-morbid factors and stroke patterns, guiding interventions to reduce diabetes rates and improve stroke outcomes. The aim of this study was to describe the distribution of co-morbidities of diabetes among hospitalized stroke patients.
Methods: To describe the pattern of co-morbidities of diabetes among hospitalized stroke patients was a descriptive study. It was done in the department of Medicine of Sir Salimullah Medical College and Mitford Hospital from January 2015-June 2015. A total of 110 patients were enrolled in the study.
Result: Patients averaged 56.95 years old (SD±6.594), with the majority (50%) aged 51-60 years. Among the 110 patients, 72 were male, most of whom (97.2%) were smokers. Half of the males had controlled diabetes, while all females had uncontrolled diabetes. Ischemic stroke affected 75% of males and 97.4% of females. About 80% of males had hypertension, compared to 92% of females. Dyslipidaemia was known in 29% of males and 37% of females. Kidney disease prevalence was low in both groups. More than half of both males (55.6%) and females (55.3%) were obese. Peripheral neuropathy was noted in 47% of males and 65.8% of females. Non-alcoholic fatty liver disease affected 28% of males and 21% of females.
Conclusion: It's crucial to implement targeted strategies for preventing and managing stroke in diabetic patients, emphasizing education and raising public awareness about diabetes and its complications.
References
Centers for Disease Control and Prevention 2014. National diabetes fact sheet. Available at: http://www.cdc.gov/diabetes. Accessed on 13th April 2015.
Extract of the Global Diabetes Scorecard Tracking Progress for Action. Brussels: International Diabetes Federation; 2015. Available at: https://diabetesatlas.org.
Centre for Disease Control of Prevention. SEARCH for Diabetes in Youth. Available at: http://www.cdc.gov/diabetes/pubs. Accessed on 13th April 2015.
Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997;349:1269-76.
Islam MN, Moniruzzaman M, Khalil MI, Basri R, Alam MK, Gan SH et al. Burden of stroke in Bangladesh. Int J Stroke. 2013;8(3):211-3.
Kissela BM, Khoury J, Kleindorfer D. Epidemiology of ischemic stroke in patients with diabetes: the greater Cincinnati/Northern Kentucky Stroke Study. Diabetes Care. 2005;28:355-9.
Folsom AR, Rasmussen ML, Chambless LE. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The atherosclerosis risk in communities (ARIC) study investigators. Diabetes Care 1999;22:1077-83.
Boden-Albala B, Sacco RL, Lee HS. Metabolic syndrome and ischemic stroke risk: Northern Manhattan Study. Stroke. 2008;39:30-5.
Pettitt DJ, Sand MR, Bennett PM. Familial predisposition to renal disease in two generations of Pima Indians with type II (non-insulin dependent) diabetes mellitus. Diabetologia. 1990;33:438.
Nathan DR, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. Diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study research group. N Engl J Med. 2005;353:2643.
Holman RR, Paul SK, Bethel MA, et al. 10 –year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577.
Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. JAMA. 1982;248(12):1465–77.
Juutilianen A. Type 2 diabetes as a “coronary heart disease equivalent”: an 18-year prospective population-based study in finish subjects. Diabetes Care. 2005;28(12):2901-7.
Hypertension in Diabetes Study Investigators. Hypertension in Diabetes Study (HDS): II, increased risk of cardiovascular complications in hypertensive type 2 diabetes patients. J Hypertension. 1993;11:319-25.
Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA. 1999;281:1291.
Dagogo-Jack S. Primary prevention of cardiovascular disease in diabetic patients. Cardio Q. 2006;12:20.
Nesto RW. Correlation between cardiovascular disease and diabetes mellitus: current concepts. Am J Med. 2004;116:11.
Congdon NG, Friedman DS, Lietman T. Important causes of visual impairment in the world today. JAMA. 2003;290:2057-60.
Varma R. From a population to patients: the Wisconsin epidemiologic study of diabetic retinopathy. Opthalmol. 2008;115:1857-8.
Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. Hypertension. 1995;26(6):869-79.
Myers BD. Pathophysiology of proteinuria in diabetic glomerular disease. J Hypertens. 1990;8:41-6.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin dependent diabetes mellitus. N Engl J Med. 1993;329:977-86.
Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003; 63:225.
Tesfaye S. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;10:2285-93.
Aronson SM. Intercranial vascular lesions in patients with diabetes mellitus. J Neuropathol Exp Neurol. 1973;23:183-96.
Adams HP, Patman SF, Kassell NF, Tomer JC. Prevalence of diabetes mellitus among patients with subarachnoid haemorrhage. Arch Neurol. 1984;41:1033-5.
Long AN, Dagogo-Jack S. The comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection. Clin Hypertens (Greenwich). 2011;13(4):244-51.
Suh DC, Choi IS, Plauschinat C, Kwon J, Baron M. Impact of comorbid conditions and race/ethnicity on glycemic control among the US population with type 2 diabetes, 1988-1994 to 1999-2004. J Diabetes Complications. 2010;24:382-91.
Plantinga LC, Crews DC, Coresh J. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol. 2010;5:673-82.
Suh DC, Choi IS, Plauschinat C, Kwon J, Baron M. Impact of comorbid conditions and race/ethnicity on glycaemic control among the US population with type 2 diabetes, 1988-1994 to 1999-2004. J Diabetes Complications. 2010;24:382-91.
Adler AI, Stratton IM, Neil HA. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412-9.
UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-13.
Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE sub study. Lancet. 2000;355:253-9.
Masood CT, Afzal W. Long-term complications of diabetes and co- morbidities contributing to atherosclerosis in diabetic population of Mirpur, Azad Kashmir. JPMA. 2013;63(11):1383-6.
Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
Hansson L, Zanchetti A, Carruthers SG. Effects of intensive blood- pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-62.
Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008;359:1565-76.
Picardi A, D'Avola D, Gentilucci UV, Galati G, Fiori E, Afeltra A: Diabetes in chronic liver disease: from old concepts to new evidence. Diabetes Metab Res Rev. 2006;22(4):274-83.
